NeuroPace Appoints Patrick Williams CFO Amid Strategic Transition

NeuroPace has appointed Patrick F. Williams as its new Chief Financial Officer, effective June 20, 2025, replacing Rebecca Kuhn who will transition to an advisory role for the next twelve months. Williams brings over 25 years of financial and operational experience in the medical device industry, having previously served as CFO at STAAR Surgical, Sientra, and Zeltiq. This leadership change aligns with NeuroPace's strategic focus on expanding access to its RNS System, which treats drug-resistant epilepsy, and aims to support the company's growth trajectory. NeuroPace recently reported strong first-quarter revenue growth of 24%, with RNS sales increasing by 26%, highlighting positive momentum for the company. Analysts generally hold an optimistic view of NeuroPace's stock, with an average price target around $17 and an 'Outperform' rating, though some financial challenges remain. The company and leadership emphasize continued commitment to innovation and value creation for patients and shareholders alike.